An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of four dose regimens
(pattern of giving treatment) of JNJ-26113100 in the treatment of adult Atopic Dermatitis
([AD]; skin rash, inflammation) that is moderate in severity.
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.